DrugPatentWatch Database Preview
Investigational Drug Information for Prexasertib
Email this page to a colleague
What is the development status for investigational drug Prexasertib?
Prexasertib is an investigational drug.
There have been 17 clinical trials for Prexasertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 10th 2018.
The most common disease conditions in clinical trials are Neoplasms, Leukemia, and Preleukemia. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and National Cancer Institute (NCI).
There are eight US patents protecting this investigational drug and one hundred and fifty-five international patents.
Summary for Prexasertib
| US Patents | 8 |
| International Patents | 155 |
| US Patent Applications | 71 |
| WIPO Patent Applications | 96 |
| Japanese Patent Applications | 11 |
| Clinical Trial Progress | Phase 2 (2018-04-10) |
| Vendors | 32 |
Recent Clinical Trials for Prexasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Memorial Sloan Kettering Cancer Center | Phase 1/Phase 2 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | Eli Lilly and Company | Phase 1 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | St. Jude Children's Research Hospital | Phase 1 |
Clinical Trial Summary for Prexasertib
Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib
US Patents for Prexasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Prexasertib | ⤷ Sign up for a Free Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| Prexasertib | ⤷ Sign up for a Free Trial | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate | Eli Lilly and Company (Indianapolis, IN) | ⤷ Sign up for a Free Trial |
| Prexasertib | ⤷ Sign up for a Free Trial | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Prexasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Prexasertib | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign up for a Free Trial |
| Prexasertib | Canada | CA3023278 | 2036-05-05 | ⤷ Sign up for a Free Trial |
| Prexasertib | China | CN107847398 | 2036-05-05 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
